Revisiting clinical trials on glycemic control and cardiovascular risk by Ferreira, Sandra Roberta Gouvea
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Diabetology & Metabolic Syndrome
Open Access Commentary
Revisiting clinical trials on glycemic control and cardiovascular risk
Sandra Roberta Gouvea Ferreira
Address: Nutrition Department, School of Public Health, University of São Paulo, Brazil
Email: Sandra Roberta Gouvea Ferreira - sandrafv@usp.br
Abstract
The most relevant clinical trials, assessing the role of glycemic control in reducing cardiovascular
risk, are examined. The UKPDS was the first to address this issue. More recent trials (ACCORD,
ADVANCE and VADT) are controversial and evidences did not support that strict glycemic
control (reflected by normal glycated hemoglobin) exclusively is sufficient to reduce cardiovascular
risk in complicated individuals with long-term type 2 diabetes mellitus. Some possible reasons for
controversies are included.
Commentary
In the last years, an increase in the cardiovascular mortal-
ity of diabetic individuals has been observed, being more
significant among diabetic women [1]. The presence of
diabetes mellitus has a deleterious effect on mortality
independently of other risk factors, resulting in a two-fold
increase in the mortality rate [2]. Recently, Haffner et al
[3] observed that diabetes is considered an equivalent of
high cardiovascular risk, as diabetic individuals, even
without a previous cardiovascular event, present an inci-
dence of myocardial infarction in a period of seven years
similar to non-diabetic individuals who have already pre-
sented cardiovascular events.
Since the 1960s, several clinical trials evaluated the role of
glycemic control in decreasing cardiovascular risk. How-
ever, by the end of the 1990s and especially in the begin-
ning of this century, the main clinical studies focusing on
the role of the glycemic control for the decrease of cardio-
vascular risk were conducted, such as the UKPDS - United
Kingdom Prospective Diabetes Study [4] and Steno-2 [5].
In this review, we will emphasize mainly the three latest
studies: the ACCORD - Action to Control Cardiovascular
Risk in Diabetes [6], ADVANCE - Action in Diabetes and
Vascular Disease - Preterax and Diamicron Modified
Release Controlled Evaluation [7] and VADT - Veterans
Affair Diabetes Trial [8].
The UKPDS [4] was the first of these studies and it was a
milestone in diabetology. The investigators observed that
individuals submitted to intensive glycemic control had a
risk reduction of 16%, which was not significant with
regards to macrovascular events, especially acute myocar-
dial infarction and sudden death. UKPDS also found that
a 1% decrease in glycated hemoglobin reduced 21% of the
risk of any diabetes-related outcome, 14% the risk of myo-
cardial infarction and 37% the risk of microangiopathy
[9]. Steno-2 [5] which was a study of intensive interven-
tion in multiple cardiovascular risk factors in type 2 dia-
betic individuals with microalbuminuria, showed that in
addition to the intensive glycemic control, the control of
other risk factors frequently observed in these individuals
such as hypertension, dyslipidemia and microalbuminu-
ria, significantly decreased the risk of cardiovascular
events and microangiopathy. The major conclusion of
Steno-2 was that the exclusive control of glycemia is not
effective for the cardiovascular protection in type 2 diabe-
tes, since a number of other risk factors - which constitute
the metabolic syndrome - must be also intensively treated.
Steno-2 has recently reported the results of the further 5-
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year continuation, after eight years of follow-up with
interventions, in a total of 13 years of follow-up [10]. The
results showed that the multifactorial intensive therapy
continued to be associated with significant benefits on the
cardiovascular system, with an even more significant
decrease regarding cardiovascular events and death than
during the initial intervention period. Should we control
glycemic levels? We actually have enough evidence to
affirm so, but in addition to controlling glycemia very
strictly, we should also control blood pressure levels, lipid
profile and other risk factors. However, it is important to
emphasize that the decrease in glycated hemoglobin
(HbA1c) while reducing the risk of chronic complications
increases the risk of hypoglycemia, which is a frequent
adverse effect during intensive control of glucose levels.
Meta-analysis has already demonstrated an independent
association between the glycemic control and the inci-
dence of cardiovascular disease in type 1 and type 2 diabe-
tes [11]. In type 1 diabetic individuals [12], it has been
observed that the increase in HbA1c was associated with a
significant increment in the incidence of peripheral arte-
rial disease, and a borderline significant increase in the
incidence of coronary heart disease, even after adjustment
for a number of risk factors. The conclusion is that there
are evidences of association between HbA1c reduction
and cardiovascular benefits in diabetes. However, up to
which level of HbA1c reduction would there be benefits to
the patient? Would the established goal of HbA1c reduce
the incidence of cardiovascular events? Randomized clin-
ical trials, particularly with type 2 diabetes individuals,
were necessary to answer this question.
To answer this question properly, clinical trials should
have several strengths. In addition to the clearness of this
question, the design should be longitudinal and long
enough to allow the occurrence of outcomes. Also, the
sample size is important as well as being randomized to
minimize bias of several natures. Taking hard outcomes
rather than surrogate outcomes is preferable, and statisti-
cal analysis should consider adjustments for a number of
confounding variables. Trials attending these characteris-
tics should generate high quality evidences. Fulfilling
most of these aspects, two studies were conducted and
recently the ACCORD [6] and ADVANCE [7], and addi-
tionally the VADT [8] results were announced in the 2008
Scientific Sessions of the American Diabetes Association.
These three trials were designed specifically to investigate
whether a more strict goal of glycated hemoglobin would
further reduce the risk of cardiovascular events in type 2
diabetes than the currently recommended goal, which is
HbA1c < 7%.
ACCORD was a study conducted in North America, with
the participation of over ten thousand patients who had
initial HbA1c > 7.5% and high risk of cardiovascular dis-
ease. The hypothesis of this arm of the ACCORD - refer-
ring to glycemic control - was that reduction of HbA1c to
less than 6% would bring more benefits with regards to
macrovascular events. An important proportion of the
patients in this study already had a cardiovascular event.
The subset allocated to the intensive glycemic control had
the goal of HbA1c < 6% while the control group had the
goal of between 7.0 and 7.9%.
The primary outcome was myocardial infarction, non-
fatal stroke and cardiovascular death; the follow-up was
initially scheduled to 5.6 years, but the glycemic arm was
interrupted prematurely with 3.6 years due to the report of
significant excess of mortality in the intensive group, in
which 257 deaths occurred, compared with 203 in the
control group.
At the beginning of the study, these individuals had a
mean age of 62 years, 35% had history of a previous car-
diovascular event, and mean value of HbA1c was 8.3% for
both groups. These were also comparable with regards to
the other variables. By the end of the follow-up period,
individuals undergoing intensive therapy presented a sig-
nificantly higher frequency of use of antidiabetic agents,
especially metformin, secretagogues and glitazone when
compared with those under standard therapy. This
resulted in HbA1c of 6.4% in the intensive group and of
7.5% in the conventional therapy group. It is important to
observe that the dropping rate of HbA1c was very fast in
the intensive therapy group. The individuals under inten-
sive therapy presented higher exposure to anti-hyperglyc-
emic drugs, had more hypoglycemia, more weight gain
and water retention, and they also used ACE inhibitors
less often.
Regarding the primary outcomes of the glycemia arm of
the ACCORD study [6], there was no statistically signifi-
cant difference between the individuals under standard
therapy and those under intensive therapy, and the latter
presented significantly higher mortality when compared
to patients under standard therapy. However, an analysis
of a sub-group Eoof individuals included in the ACCORD
who had not had previous cardiovascular disease showed
that these individuals also reach benefits from the inten-
sive treatment. The patients who presented lower HbA1c
at the beginning of the study apparently also had benefits
from the intensive therapy.
The most frequent adverse effect in the ACCORD [6]
group under intensive therapy, as expected, was hypogly-
cemia and especially severe hypoglycemia. This group also
presented higher frequency of water retention and weight
gain > 10 kg in 28% of the patients enrolled. Summing up,
the main findings of ACCORD, in type 2 diabetes individ-Diabetology & Metabolic Syndrome 2009, 1:12 http://www.dmsjournal.com/content/1/1/12
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uals with high cardiovascular risk and initial HbA1c >
7.5%, the therapy seeking a more strict glycemic control,
i.e., HbA1c < 6% in 3.6 years, increased all-cause mortality
rates, in addition to a higher weight gain and more
hypoglycemic events. Considering the combination of
primary outcomes, the ACCORD does not support the
hypothesis of benefit from intensive glycemic control to
the reduction of cardiovascular events in patients with
high cardiovascular risk.
The ACCORD [6] had several favorable aspects such as
hard outcomes, the sample size (involving a high number
of participants) and the statistical analyses were carefully
performed. Among the unfavorable aspects of the study,
we mention the selection of patients with high cardiovas-
cular risk, which possibly do not represent most of the
patients in our offices and outpatient clinics, limiting to
generalize these results to the whole population of diabet-
ics. Other unfavorable aspects were the multiple possibil-
ities of drug interactions and the follow-up of 3.6 years,
which may be considered relatively short to assess hard
cardiovascular outcomes. The possible explanations
argued for these unexpected ACCORD results could be
related to drugs such as rosiglitazone or deleterious drug
interactions. Apparently, this was not the case, because in
the analysis involving the subgroup of patients who used
rosiglitazone, no higher occurrence of these undesirable
effects was observed. The higher frequency of hypoglyc-
emia should be related to the multiple insulin doses or to
the aggressive and/or fast approach to achieve the glyc-
emic goal (HbA1c level < 6% was low).
The ADVANCE study [7] was conducted in several coun-
tries, with over 11 thousand patients aged over 55 years
old. Similarly to the ACCORD [6], its objective was to
assess the reduction of combined micro and macrovascu-
lar events, in type 2 diabetes patients with history of
micro- or macrovascular disease or presenting risk factors,
through intensive glycemic control, under a regimen
based on sulfonylurea, as initially all the individuals used
gliclazide. The study had HbA1c of 6.5% as a goal, inten-
sive blood pressure control with a fixed combination of
ACE inhibitor plus a diuretic. The study was divided into
intensive or standard glycemic control, and these two
arms were subdivided into two treatment groups for
hypertension, intensive and standard groups. This study
also had as primary outcomes macrovascular disease,
which would be the combination of stroke, non-fatal inf-
arction and cardiovascular death, but it also included
microvascular events, defined as the appearance or wors-
ening of retinopathy and nephropathy. Both groups pre-
sented, at the beginning of the study, mean HbA1c of
7.5%, and its decrease in the intensive group up to the
goal of 6.5% was slower in the first months, than observed
in the ACCORD study [6]. Regarding the fasting glycemia,
the behavior was similar. Favorable results regarding the
primary outcome - combining macro- and microvascular
events - were statistically significant in the intensive treat-
ment group, but when we separate macro- from microvas-
cular events, we observe that the decrease in microvascular
events was remarkable, but not in macrovascular events.
The frequency of hypoglycemia was higher in the inten-
sive treatment group, but the frequency of severe hypogly-
cemia in this study was very lower than that observed in
the ACCORD study [6].
As main findings of this study, we would say that the
intensive glycemic control resulted in a 10% decrease in
the composite outcome, 14% decrease in microvascular
events, 21% in nephropathy, but without significant effect
regarding macrovascular events and cardiovascular mor-
tality. Regarding the reduction of microangiopathy, previ-
ous studies, such as UKPDS [4], had already shown that
the intensive control resulted in significant improvement.
However, regarding the absence of effects at least deleteri-
ous on the cardiovascular system, it was different from the
already shown findings of the ACCORD [6]. These two
studies present similarities: as they had no conflicts of
interest with private companies, sample sizes were similar
and expressive, both presented high power to detect the
risk decrease, both analyzed data by intention to treat
technique, HbA1c at baseline in the standard and inten-
sive groups were similar, one third of the patients in both
studies presented previous family history of cardiovascu-
lar disease. However, they presented some differences: in
the ACCORD, individuals were older; baseline HbA1c was
lower in the ADVANCE [7] when compared to the
ACCORD; the glycated hemoglobin goals were lower in
the ACCORD, 6% as compared to the ADVANCE, which
was 6.5%, and the rate to achieve these goals were also dif-
ferent from one study to another. For instance, in the
ACCORD, there was a 1.4% decrease in HbA1c in the first
four months, while in the ADVANCE, HbA1c decreased
0.5% in the first six months and further 4.4% in the fol-
lowing six months. The primary outcomes were also dif-
ferent: in the ACCORD, it was purely cardiovascular and
in the ADVANCE study, it was a combination of micro-
and macrovascular outcomes, and death was a secondary
outcome in the ADVANCE.
Possible reasons for these contrasting results are: out-
comes were not comparable, different frequencies and
drug types were used, e.g. when it comes to glitazones, in
the ADVANCE, less than 20% of patients were under such
therapy, and in the ACCORD, over 90% of patients in
intensive therapy were using the drug. The follow-up
period was also shorter in the ACCORD study when com-
pared to 5 years in the ADVANCE, hypoglycemia was
more frequent and there was considerable weight gain,Diabetology & Metabolic Syndrome 2009, 1:12 http://www.dmsjournal.com/content/1/1/12
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3.5 kg on average, only in the ACCORD, specifically in the
group of intensive therapy.
The VADT [8] was the third large study of tight blood glu-
cose control, in which war veterans from 20 Veterans'
Association Hospitals in U.S. were enrolled. Patients with
poorly controlled type 2 diabetes were randomized to
either intensive glucose control or standard therapy. The
goal was a HbA1c value < 7% for the group under inten-
sive therapy and 8-9% for the group under standard ther-
apy and the primary outcome of the study were
macrovascular complications.
VADT [8] included a much smaller sample (n = 1,791)
than the studies previously mentioned, aged over 60 years
old, body mass index compatible with obesity, with
uncontrolled diabetes using one or more oral agents or
insulin, following an algorhythm which started the treat-
ment with metformin for obese individuals or sulfonylu-
rea for non-obese patients, associating gradually other
oral agents, including insulin. The individuals had a
known period of diabetes diagnosis of 12 years and they
had already presented a very elevated frequency of chronic
complications of diabetes, and hemoglobin at the begin-
ning of the study was 9.4%. The study length was 7.6 years
and the primary outcomes were only cardiovascular
events (myocardial infarction, death, stroke, cardiac fail-
ure, amputation due to peripheral arterial disease, surgical
intervention or angioplasty and critical ischemia in
limbs).
Individuals were stratified into two types of treatment:
intensive and standard, the number of individuals who
presented events in the groups was not different, the aver-
age of HbA1c after six years of follow-up in the standard
group was around 8.4%, while in the group under inten-
sive treatment, it was 6.9%. The conclusion of the VADT
investigators was that in an advanced age population,
with long-term diabetes and chronic complications, it is
more difficult to manage the therapy, but it is possible to
obtain significant improvement in glycemic levels and in
the other risk factors of these individuals; however, iso-
lated glycemic control does not have significant effect in
reducing cardiovascular events.
Considering that the rates of cardiovascular events found
in these studies were lower than the previously described
ones, we may infer that the modern therapies for type 2
diabetes have significantly benefits to these patients. It is
necessary to establish the level of glycemic control which
will be favorable to the patient, either with high or low
cardiovascular risk, as well as to define the ideal rate to
achieve such control level. Finally, the effects of drug com-
binations should also be investigated.
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